Intravesical Gemcitabine: State of the Art

European Urology, Supplements

Volumn 6, Issue 14, 2007, Pages 809-815

  Gontero, Paolo ^a   Tizzani, Alessandro ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

BCG refractory; Gemcitabine; Intravesical; Superficial bladder cancer

Indexed keywords

BCG VACCINE; EPIRUBICIN; GEMCITABINE; MITOMYCIN C;

ARTHRALGIA; ASTHENIA; BLADDER CANCER; BLADDER SPASM; BONE MARROW SUPPRESSION; CANCER PREVENTION; CHILL; CLINICAL ASSESSMENT; CLINICAL TRIAL; DISEASE MARKER; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG SAFETY; DYSURIA; FATIGUE; HEADACHE; HEMATURIA; HUMAN; LEUKOPENIA; LIVER TOXICITY; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STOMACH DISEASE; THROMBOCYTOPENIA; TRANSURETHRAL RESECTION; TREATMENT RESPONSE; URINARY FREQUENCY; URINE INCONTINENCE; URINE RETENTION; VOMITING;

EID: 34347212455     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2007.05.002     Document Type: Review

References (37)

1. Oosterlinck W., Lobel B., Jakse G., et al. Guidelines on bladder cancer. European Association of Urology (EAU) Working Group on Oncological Urology. Eur Urol 41 (2002) 105-112
2. Lamm D.L. Intravesical therapy for superficial bladder cancer: slow but steady progress. J Clin Oncol 21 (2003) 4259-4260
3. Huncharek M., and Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation. Am J Clin Oncol 26 (2003) 402-407
4. Sylvester R.J., van der Mejden A.P., and Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168 (2002) 1964-1970
5. Bohle A., and Bock P.R. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 63 (2004) 682-686
6. Bohle A., Jocham D., and Bock P.R. Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169 (2003) 90-95
7. Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2003:CD003231.
8. Huncharek M., and Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am J Clin Oncol 27 (2004) 522-528
9. Joudi F.N., Smith B.J., O'Donnell M.A., and Konety B.R. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 175 (2006) 1634-1639
10. Koya M.P., Simon M.A., and Soloway M.S. Complications of intravesical therapy for urothelial cancer of the bladder. J Urol 175 (2006) 2004-2010
11. van der Meijden A.P., Sylvester R.J., Oosterlinck W., et al. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44 (2003) 429-434
12. Bergman A.M., Pinedo H.M., and Peters G.J. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5 (2002) 19-33
13. Stadler W.M., Kuzel T., Roth B., Raghavan D., and Dorr F.A. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15 (1997) 3394-3398
14. Lorusso V., Pollera C.F., Antimi M., et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34 (1998) 1208-1212
15. Odonnel M.A., Evanoff D., and Luo Y. Studies on Gemcitabine as an intravesical agent for superficial bladder cancer. J Urol 4 Suppl (2003) 508
16. Matera M., Costantino G., Clementi G., et al. Experimental study on the toxicity and the local and systemic tolerability of gemcitabine after topical treatment of the rabbit bladder. Oncol Rep 11 (2004) 1145-1151
17. Witjes J.A., Vriesema J.L., van der Heijden A.G., et al. Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs. Eur Urol 44 (2003) 615-619
18. Dalbagni G., Russo P., Sheinfeld J., et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 20 (2002) 3193-3198
19. Laufer M., Ramalingam S., Schoenberg M.P., et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 21 (2003) 697-703
20. Witjes J.A., van der Heijden A.G., Vriesema J.L., et al. Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol 45 (2004) 182-186
21. De Berardinis E., Antonini G., Peters G.J., et al. Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation. BJU Int 93 (2004) 491-494
22. Palou J., Carcas A., Segarra J., et al. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer. J Urol 172 (2004) 485-488
23. Hall R.R. Transurethral resection for transitional cell carcinoma. Problems Urol 6 (1992) 460-470
24. Van der Meijden A.P.M., Hall R.R., Pavone Macaluso M., et al. Marker tumour response to the sequential combination of intravesical therapy with mitomycin C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organization for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897). Eur Urol 29 (1996) 199-203
25. Calais da Silva F., Denis L., Bono A., et al. Intravesical chemoresection with 4′-epi-doxorubicin in patients with superficial bladder tumors. Eur Urol 14 (1988) 207-209
26. Van der Meijden A., Hall R.R., Pavone Macaluso M., et al. Marker tumour response to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Eur Urol 29 (1996) 199-203
27. Popert R.J.M., Goodall J., Coptcoat M.J., et al. Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin. Br J Urol 74 (1994) 195-196
28. Fellows G., Parmar M., Grigor R., et al. Marker tumour response to Evans and Pasteur BCG in multiple recurrent pTa, pT1 bladder tumours: report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br J Urol 73 (1994) 639-644
29. Mack D., Holtl W., Bassi P., et al. The ablative effect of quarter dose BCG on a papillary lesion of the bladder. J Urol 165 (2001) 401-403
30. Calais da Silva F.M., and Calais da Silva F.E. Phase 2 study 2000mg of intravesical gemcitabine in marker lesions. Eur Urol Suppl 4 3 (2005) 222 (abstract no. 877)
31. Gontero P., Casetta G., Maso G., et al. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 46 (2004) 339-343
32. Maffezzini M., Campodonico F., Canepa G., Capponi G., and Fontana V. Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder. Eur Urol 51 (2007) 956-961
33. Serretta V., Galuffo A., Pavone C., Allegro R., and Pavone-Macaluso M. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder: phase I-II study on marker lesion. Urology 65 (2005) 65-69
34. Gardmark T., Carringer M., Beckman E., Malmstrom P.U., and members of the Intravesical Gemcitabine Study Group. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder. Urology 66 (2005) 527-530
35. Bartoletti R., Cai T., Gacci M., et al. Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study. Urology 66 (2005) 726-731
36. Conti G., and the AURO (Associazione Urologi Ospedalieri) Group. Prospective phase II study on intravesical gemcitabine in intermediate risk SBC recurring after previous intravescial therapy. Arch Ital Urol Androl (2005) Abst 241
37. Brausi M., Giussani L., Altieri V., et al. Phase II marker lesion study of 6-week intravesical gemcitabine instillation in patients with low risk non muscle invasive bladder tumours. Eur Urol Suppl 6 (2007) 59 (abstract no. 148)